NOVEN PHARMACEUTICALS INC.

History

YearDetail
1987 Founded in 1987 by Steven Sablotsky, Noven Pharmaceuticals Inc. specializes in developing and manufacturing advanced transdermal drug delivery products, technologies, and prescription transdermal products.
1999 The company launched Vivelle-Dot (estradiol transdermal system), which was the world's smallest estrogen patch at the time.
2007 The company acquired JDS Pharmaceuticals LLC, a privately held specialty pharmaceutical company that marketed two branded prescription psychiatry products, for approximately $125 million in cash.
2009 To expand into the U.S., Noven was acquired by Hisamitsu Pharmaceutical Co. Ltd., a Japanese company that began manufacturing and marketing prescription drugs during the 1970s. 
2012 The company acquired commercial rights to Minivelle (estradiol transdermal system) in the U.S. and Canada from Novogyne Pharmaceuticals, a women’s health joint venture between Noven and Novartis.
2023 The company launched XELSTRYM, a transdermal patch for the treatment of ADHD. It marked the first and only once-daily amphetamine transdermal patch available for both adults and pediatric patients 6 years and older. 
AI Sentiment